Update on narcolepsy
- 247 Downloads
The last two decades have seen an explosion in our understanding of the clinical nature of narcolepsy and its pathogenesis, fuelling new approaches to potentially effective treatments. It is now recognised that the full narcoleptic syndrome has significant adverse effects on sleep regulation across the full 24-h period and is often associated with clinical features outside the sleep–wake domain. The discovery that most narcoleptic subjects specifically lack a hypothalamic neuropeptide (hypocretin, also called orexin) was a truly original and landmark observation in 1999, greatly furthering our understanding both of the syndrome itself and sleep biology in general. An autoimmune pathophysiology has long been suggested by the tight association with specific histocompatibility antigens and very recently partly confirmed by detailed analysis of T-cell immunological function in affected subjects. Drug treatments remain symptomatic but may soon become more focussed by restoring central hypocretin signalling with replacement therapy. Potentially disease-modifying, immunological approaches have yet to be studied systematically, although the interval between disease onset and development of the full clinical syndrome may be longer than previously appreciated, affording a realistic window of opportunity for limiting neuronal damage in this disabling condition.
KeywordsNarcolepsy Hypocretin Cataplexy Autoimmunity
Compliance with ethical standards
Conflicts of interest
The author has no conflicts of interest to declare.
- 21.Dimitrova A, Fronczek R, van der Ploeg J et al (2011) Reward-seeking behaviour in human narcolepsy. J Clin Sleep Med 7:293–300Google Scholar
- 23.The American Academy of Sleep Medicine (2012) The international classification of sleep disorders: diagnostic and coding manual, 3rd edn. AASM, ChicagoGoogle Scholar
- 44.Alshaikh MK, Tricco AC, Tashkandi M et al (2012) Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med 15:451–458Google Scholar
- 47.Abad VC, Guilleminault C (2018) Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea. Expert Rev Respir Med 2:1–13Google Scholar